These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15912847)

  • 1. [Overactive bladder].
    Krankenpfl J; 2005; 43(1-3):60. PubMed ID: 15912847
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
    Cardozo L; Dixon A
    J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
    Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F
    Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solifenacin and darifenacin for overactive bladder.
    Obstet Gynecol; 2005 Aug; 106(2):401-2. PubMed ID: 16055596
    [No Abstract]   [Full Text] [Related]  

  • 5. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.
    Serra DB; Affrime MB; Bedigian MP; Greig G; Milosavljev S; Skerjanec A; Wang Y
    J Clin Pharmacol; 2005 Sep; 45(9):1038-47. PubMed ID: 16100298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
    Foote J; Glavind K; Kralidis G; Wyndaele JJ
    Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
    Hill S; Khullar V; Wyndaele JJ; Lheritier K;
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug patch tips and tricks for general practice].
    Alloussi S
    Krankenpfl J; 2005; 43(7-10):186. PubMed ID: 16515259
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bamberg Discussions 2003. Diagnosis and therapy of urinary incontinence in diabetic patients].
    Madersbacher H
    Krankenpfl J; 2003; 41(7-9):176-7. PubMed ID: 14705533
    [No Abstract]   [Full Text] [Related]  

  • 10. Darifenacin in the treatment of overactive bladder.
    Haab F
    Drugs Today (Barc); 2005 Jul; 41(7):441-52. PubMed ID: 16193097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solifenacin and darifenacin for overactive bladder.
    Med Lett Drugs Ther; 2005 Mar; 47(1204):23-4. PubMed ID: 15767976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow.
    Chapple CR; Abrams P
    Eur Urol; 2005 Jul; 48(1):102-9. PubMed ID: 15936869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.
    Zinner N; Tuttle J; Marks L
    World J Urol; 2005 Sep; 23(4):248-52. PubMed ID: 16096831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Less disability in daily activities].
    Krankenpfl J; 2005; 43(7-10):191. PubMed ID: 16515263
    [No Abstract]   [Full Text] [Related]  

  • 15. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.
    Zinner N
    Expert Opin Pharmacother; 2007 Mar; 8(4):511-23. PubMed ID: 17309345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
    Kay GG; Wesnes KA
    BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darifenacin: Pharmacology and clinical usage.
    Steers WD
    Urol Clin North Am; 2006 Nov; 33(4):475-82, viii. PubMed ID: 17011383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darifenacin: in the treatment of overactive bladder.
    Croom KF; Keating GM
    Drugs Aging; 2004; 21(13):885-92; discussion 893-4. PubMed ID: 15493952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urgency, botulinum toxin and how botulinum toxin can help urgency.
    Chancellor MB
    J Urol; 2005 Sep; 174(3):818. PubMed ID: 16093961
    [No Abstract]   [Full Text] [Related]  

  • 20. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
    Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
    Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.